702 related articles for article (PubMed ID: 9497881)
1. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
[TBL] [Abstract][Full Text] [Related]
3. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.
Meikle AW; Arver S; Dobs AS; Adolfsson J; Sanders SW; Middleton RG; Stephenson RA; Hoover DR; Rajaram L; Mazer NA
Urology; 1997 Feb; 49(2):191-6. PubMed ID: 9037280
[TBL] [Abstract][Full Text] [Related]
4. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
[TBL] [Abstract][Full Text] [Related]
6. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
[TBL] [Abstract][Full Text] [Related]
7. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
13. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
Winters SJ; Atkinson L
Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
[TBL] [Abstract][Full Text] [Related]
14. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
16. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
17. Transdermal testosterone.
McClellan KJ; Goa KL
Drugs; 1998 Feb; 55(2):253-8; discussion 259. PubMed ID: 9506244
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
[TBL] [Abstract][Full Text] [Related]
19. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Gittelman M; Jaffe JS; Kaminetsky JC
J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
[TBL] [Abstract][Full Text] [Related]
20. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
